Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Legislation
House Speaker Pelosi’s amended HR 3 expands scope of targeted drugs, adds manufacturer transparency requirements ahead of dual markups and a hearing on 17 October.
A new bill giving the UK regulator more powers after Brexit has been welcomed by the life sciences industry. However, observers have warned that it needs fleshing out with detail, and that the government would be wise to proceed carefully if it considers relaxing clinical trial regulations.
Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.
Overall effect on health of US families stemming from increased use of drugs but decreased availability of new drugs is 'unclear,' the Congressional Budget Office concludes in its preliminary analysis of HR 3.
PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.
Governor Newsom signs bill that presumes brand-generic patent settlements are anticompetitive; AAM says the law violates US Constitution by attempting to regulate transactions outside the state.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.